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Abstract
Background: Pancreatic carcinoma usually is a fatal disease with no cure, mainly due to its invasion
and metastasis prior to diagnosis. We analyzed the gene expression profiles of paired primary
pancreatic tumors and metastatic lesions from Ela-c-myc transgenic mice in order to identify genes
that may be involved in the pancreatic cancer progression. Differentially expressed selected genes
were verified by semi-quantitative and quantitative RT-PCR. To further evaluate the relevance of
some of the selected differentially expressed genes, we investigated their expression pattern in
human pancreatic cancer cell lines with high and low metastatic potentials.
Results: Data indicate that genes involved in posttranscriptional regulation were a major functional
category of upregulated genes in both primary pancreatic tumors (PT) and liver metastatic lesions
(LM) compared to normal pancreas (NP). In particular, differential expression for splicing factors,
RNA binding/pre-mRNA processing factors and spliceosome related genes were observed,
indicating that RNA processing and editing related events may play critical roles in pancreatic tumor
development and progression. High expression of insulin growth factor binding protein-1 (Igfbp1)
and Serine proteinase inhibitor A1 (Serpina1), and low levels or absence of Wt1 gene expression
were exclusive to liver metastatic lesion samples.
Conclusion: We identified Igfbp1, Serpina1 and Wt1 genes that are likely to be clinically useful
biomarkers for prognostic or therapeutic purposes in metastatic pancreatic cancer, particularly in
pancreatic cancer where c-Myc is overexpressed.
Background
Pancreatic cancer (PC) is the fourth leading cause of can-
cer death in the United States and has no cure, partly
because the tumor is at advanced stage or has already
metastasized at the time of diagnosis [1]. Like many other
types of cancer, pancreatic cancer also shows high fre-
quencies of overexpression and/or amplification of the c-
myc oncogene. In one study, 43.5% of primary tumors
and 31.6% of metastases showed c-Myc overexpression, in
association with 32.5% and 29.4% of gene amplification
in the primary and metastatic lesions, respectively [2]. c-
Myc and cyclin D1 gene amplification was report 54%
and 28% in 31 pancreatic cancer cell lines, respectively,
indicating a high frequency of concomitant amplification
of both genes [3]. Moreover, simultaneous amplification
of activated k-ras and c-myc has been found in both pri-
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mary tumor and lymph node metastasis, suggesting that c-
Myc may collaborate with other oncogenes to promote
development and progression of pancreatic cancer [4].
More direct evidence for a critical role for c-Myc in pancre-
atic carcinogenesis comes from Ela-c-myc transgenic mice
that develop PC between 2–7 months of age with 100%
incidence rate [5]. One-half of the pancreatic tumors that
form in this mouse model are acinar cell adenocarcino-
mas, while the remaining half of the tumors are mixed
ductal and acinar cell carcinomas embedded in dense
stroma. We have recently described detailed morphologi-
cal traits of the pancreatic tumors developed in this trans-
genic model [6,7] and, for the first time, observed
spontaneous metastasis to the liver in this model. These
transgenic mice are among the few animal models of liver
metastasis of spontaneous PC. The whole carcinogenic
process, from initiation to metastasis, is short (in only a
few months time) and is initiated by only one gene.
The most devastating aspect of all types of cancer, particu-
larly pancreatic cancer, is the emergence of metastases in
organs distant from the primary tumor, and this remains
the primary cause for the poor survival of patients with
pancreatic cancer [8]. Therefore, a search for molecular
markers that can predict poor prognosis and also serve as
novel targets for the development of therapies against this
most aggressive disease is warranted. Transgenic animals
have been widely used to dissect the role of genes and
molecular pathways in cancer [9]. Our transgenic model
will help in understanding the molecular mechanisms by
which metastases are generated, which is crucial for the
prevention and treatment of metastatic disease. In this
study we attempted to identify genes that may be respon-
sible for the liver metastasis of pancreatic tumors in Ela-
myc transgenic mice.
Results
cDNA Microarray Analysis and Global Gene Expression 
Profiles
Microarray signal values were calculated from the multi-
ple probes present on each chip for each condition and
each condition was repeated at least three times. The rela-
tive intensity (fold change) of gene expression levels in the
primary tumors (PT) compared to the normal pancreas
(NP) is shown in Figure 1A (left panel) and fold change in
gene expression in liver metastatic (LM) lesions compared
to PT are presented in Figures 1A (right panel).
Cluster analysis was used to display the gene expression
data of those, which showed 4-fold higher or 4-fold lower
expression levels in PT and LM compared to NP samples.
Before clustering, a filtering procedure eliminated genes
with uniformly low expression or with low expression var-
iation across the replicates. A large number of genes in PT
and LM showed different expression from NP. However,
the majority of genes did not show obvious distinction in
their expression pattern between the PT and LM (Fig. 1B),
except for a small number of genes (boxed area in Fig. 1B
expanded in Fig. 1C), suggesting that the LM largely retain
the properties of the primary tumors.
Identification of potential tumor promoting genes in c-
myc-induced pancreatic tumors
Expressed genes were categorized on the basis of their
functional properties, which showed at least 4-fold
higher, or 4-fold lower expression levels in primary or
metastatic pancreatic tumors compared to normal pan-
creas. Table 1 shows genes whose expression was upregu-
lated in PT compared to NP (relative fold change) and
also shows the relative fold change in LM compared to PT
samples. Many upregulated genes such as Birc5, Ccna2,
Ccnb1, Ccnb2, Mcm7, Nap1l1, Rad51, Smc4l1, Smc2l1,
Rsk4, sfrs1, and sfrs2 (please see Table 1 for their full
names) showed 5–20 fold higher expression levels, very
few showed exceptionally high fold changes, for example
calcium binding protein-S100g showed 109 fold higher
expression level in PT than in NP. A large number of
upregulated genes in PT belonged to the functional cate-
gories known for cell proliferation and cell cycle regula-
tion, chromosomal organization and biogenesis, and
RNA processing and modification. In Table 2, we show
the genes whose expression was down regulated in PT
compared to NP samples (relative fold change) as well as
the fold change in LM compared to PT samples. Down
regulation of some of the genes in Table 2 including
Col4a4, Pcdh17, Muc2, Muc13 (please see Table 2 for
their full names) has been shown to modulate cell adhe-
sion and apoptosis.
Selected genes (highlighted in Table 1, 2 and 3) from var-
ious functional categories were further verified by RT-PCR
for their expression patterns (Fig. 2A). This selection was
based on results in the literature indicating a direct or
indirect role for each candidate gene in RNA processing,
cell signaling, cell proliferation or apoptosis and cell
adhesion and motility activities resulting in tumor growth
and tumor progression. Many of these genes listed in
Table 1and 2, such as Birc5, Brca1, Ccnb2, CXCR4, Mcm2,
Mcm4, Mcm7, Nap1l1, Rad51, Sf3b, S100g [10-17]have
been shown to be upregulated, while Cldn18, Muc2,
Muc13, and b-myc [18-21]are shown to be down regu-
lated in human pancreatic cancer as well as other types of
cancer (please see Table 1 and 2for their full names).
However, strong expression of Muc13 in 50% of samples
as well as b-myc in pancreatic cancer cells was unexpected
and needs further characterization.
We evidenced notable changes in the family members of
insulin-like growth factor (Igf). While Igf1 expression was
slightly decreased in tumors compared with normal pan-Molecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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Gene expression profiles Figure 1
Gene expression profiles. A) Histogram showing a similar (left) and differential (right) gene expression profiles of primary 
pancreatic tumors and liver metastatic lesions from Ela-c-Myc transgenic mice compared to normal pancreas from wild type lit-
termates. B) Hierarchical clustering of differentially expressed genes. Clustering tree illustrate the expression pattern and sim-
ilarity in primary pancreatic tumors (labeled as PT) and liver metastatic lesions (labeled as LM) compared to normal pancreas 
(labeled as NP) indicated by color bars. C) Shows only the differentially expressed gene profile with at least a four-fold change 
(≤4 or ≥4) indicated by color bars. (blue-down regulated and red up-regulated).
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Table 1: Upregulated genes in primary pancreatic tumors. Relative fold change in primary pancreatic tumors compared to normal 
pancreas (PT/NP) and in liver metastatic lesions compared to primary pancreatic tumors (LM/PT).
Entrez Gene Fold change 
LM*/PT*
Fold change 
PT/NP*
Gene Symbol Gene description Ref.*
Mitochondrial ribosomal subunits
77721 1.0 4.2 Mrps5 Mitochondrial ribosomal protein S5
69527 1.0 4.5 Mrps9 Mitochondrial ribosomal protein S9
94063 1.0 4.1 Mrpl16 Mitochondrial ribosomal protein L16
56284 0.9 5.0 Mrpl19 Mitochondrial ribosomal protein L19
66407 0.8 4.1 Mrps15 Mitochondrial ribosomal protein S15
64655 1.2 7.6 Mrps22 Mitochondrial ribosomal protein S22
64658 1.0 4.1 Mrps25 Mitochondrial ribosomal protein S25
Nucleolar and nucleosome assembly proteins
53605 0.9 13.5 Nap1l1 Nucleosome assembly protein 1-like 1 10, 11
110109 0.9 4.3 Nol1 Nucleolar protein 1
52530 1.0 10.0 Nola2 Nucleolar protein family A, member 2
100608 1.1 9.4 Noc4l Nucleolar complex associated 4 homolog
55989 0.8 6.3 Nol5 Nucleolar protein 5
67134 0.9 7.8 Nol5a Nucleolar protein 5A
Small nuclear ribonucleoprotein complex
68981 1.1 8.7 Snrpa1 Small nuclear ribonucleoprotein polypeptide A'
20638 0.9 8.3 Snrpb Small nuclear ribonucleoprotein B
20641 1.1 7.1 Snrpd1 Small nuclear ribonucleoprotein D1
67332 1.1 7.4 Snrpd3 Small nuclear ribonucleoprotein D3
69878 1.1 6.9 Snrpf Small nuclear ribonucleoprotein polypeptide F
666609 1.0 7.6 Snrpg small nuclear ribonucleoprotein polypeptide G
Splicing factor
110809 1.1 5.5 Sfrs1 Splicing factor, arginine/serine-rich 1 (ASF/SF2)
20382 1.1 5.1 Sfrs2 Splicing factor, arginine/serine-rich 2 (SC-35)
20383 1.1 5.0 Sfrs3 Splicing factor, arginine/serine-rich 3 (SRp20)
81898 1.2 5.2 Sf3b1 Splicing factor 3b, subunit 1 15
66125 1.2 8.0 Sf3b5 Splicing factor 3b, subunit 5 15
225027 1.2 4.1 Sfrs7 Splicing factor, arginine/serine-rich 7
RNA binding and pre-mRNA processing factors
28000 1.1 4.7 Prpf19 PRP19/PSO4 pre-mRNA processing factor 19 homolog
68988 1.1 5.0 Prpf31 PRP31 pre-mRNA processing factor 31 homolog (yeast)
56194 1.1 5.8 Prpf40a PRP40 pre-mRNA processing factor 40 homolog A (yeast)
56275 0.9 5.5 Rbm14 RNA binding motif protein 14
67071 1.0 16.2 Rps6ka6 (Rsk4) Ribosomal protein S6 kinase polypeptide 6
Spliceosome complex
81898 1.2 5.2 Sf3b1 Splicing factor 3b, subunit 1 15
66125 1.2 8.0 Sf3b5 Splicing factor 3b, subunit 5 15
20382 1.1 4.9 Sfrs2 Splicing factor, arginine/serine-rich 2 (SC-35)
68981 1.1 8.7 Snrpa1 Small nuclear ribonucleoprotein polypeptide A'
20638 0.9 8.3 Snrpb Small nuclear ribonucleoprotein B
20641 1.1 7.1 Snrpd1 Small nuclear ribonucleoprotein D1
69878 1.1 6.9 Snrpf Small nuclear ribonucleoprotein polypeptide F
666609 1.0 7.6 Snrpg small nuclear ribonucleoprotein polypeptide G
Cell proliferation and cell cycle regulation related genes
12428 1.0 16.6 Ccna2 Cyclin A2
268697 1.2 11.2 Ccnb1 Cyclin B1
12429 1.1 17.9 Ccnb1-rs1 Cyclin B1, related sequence 1
12442 0.9 17.8 Ccnb2 Cyclin B2 15, 25
12448 1.3 4.9 Ccne2 Cyclin E2
12449 0.9 8.9 Ccnf Cyclin F
17216 0.9 9.0 Mcm2 Minichromosome maintenance deficient 2 14
17215 0.9 8.6 Mcm3 Minichromosome maintenance deficient 3
17217 1.2 8.6 Mcm4 Minichromosome maintenance deficient 4 10
17218 1.0 11.8 Mcm5 Minichromosome maintenance deficient 5
17219 1.1 20.1 Mcm6 Minichromosome maintenance deficient 6
17220 0.9 11.0 Mcm7 Minichromosome maintenance deficient 7 14
70024 1.1 6.3 Mcm10 Minichromosome maintenance deficient 10Molecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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11799 1.0 11.1 Birc5 Baculoviral IAP repeat-containing 5
12211 1.0 4.4 Birc6 Baculoviral IAP repeat-containing 6
12189 1.0 5.5 Brca1 Breast cancer 1
70099 0.9 17.3 Smc4l1 Structural maintenance of chromosomes 4
19361 1.0 15.1 Rad51 RAD51 homolog (S. cerevisiae)
Cell adhesion and migration
12774 1.1 6.7 Ccr5 Chemokine (C-C motif) receptor 5
56492 1.4 6.6 Cldn18 Claudin 18 25
Cell communication and signal trasduction
75590 0.8 30.3 Dusp9 Dual specificity phosphatase 9
67071 1.0 16.2 Rps6ka6 (Rsk4) Ribosomal protein S6 kinase polypeptide 6
12774 1.1 6.7 Ccr5 Chemokine (C-C motif) receptor 5
56275 0.9 5.5 Rbm14 RNA binding motif protein 14
12309 0.7 109.4 S100g S100 calcium binding protein G 10, 25
Apoptosis regulation related
11799 1.0 11.1 Birc5 Baculoviral IAP repeat-containing 5 16
17218 1.0 11.8 Mcm5 Minichromosome maintenance deficient 5,
17319 1.1 6.8 Mif Macrophage migration inhibitory factor
Chromosome organization and biogenesis
14211 1.1 12.7 Smc2l1 Structural maintenance of chromosomes 2
70099 0.9 17.3 Smc4l1 Structural maintenance of chromosomes 4
226026 1.0 5.4 Smc5l1 Structural maintenance of chromosomes 5
19361 1.0 15.1 Rad51 RAD51 homolog (S. cerevisiae) 12
12189 1.0 5.5 Brca1 Breast cancer 1
53605 0.9 13.5 Nap1l1 Nucleosome assembly protein 1-like 1 10, 11
17216 0.9 9.0 Mcm2 Minichromosome maintenance deficient 2 mitotin
17218 1.0 11.8 Mcm5 Minichromosome maintenance deficient 5
Transcriptional regulator
22431 0.6 2.7 Wt1 Wilms' tumor suppressor gene 57
NP = Normal pancreas; PT = Primary pancreatic tumor; LM = liver metastatic lesion; Ref.* = References identifying genes previously 
shown to have deregulated expression in pancreatic cancer
Table 1: Upregulated genes in primary pancreatic tumors. Relative fold change in primary pancreatic tumors compared to normal 
pancreas (PT/NP) and in liver metastatic lesions compared to primary pancreatic tumors (LM/PT). (Continued)
Table 2: Downregulated genes in primary pancreatic tumors. Relative fold change in primary pancreatic tumors compared to normal 
pancreas (PT/NP) and in liver metastatic lesions compared to primary pancreatic tumors (LM/PT)
Entrez Gene# Fold change 
LM/PT
Fold change 
PT/NP
Gene Symbol Gene description Ref.*
Cell adhesion, motility and migration
12340 0.84 -11.6 Capza1 Capping protein (actin filament) muscle Z-line, alpha 1 16
12829 0.98 -10.8 Col4a4 Procollagen, type IV, alpha 4
13643 1.02 -7.6 Efnb3 Ephrin B3
215384 1.03 -8 Fcgbp Fc fragment of IgG binding protein
16855 1.00 -6.4 Lgals4 Lectin, galactose binding, soluble 4
17831 1.02 -40 Muc2 Mucin 2
219228 1.51 -18.8 Pcdh17 Protocadherin 17
68799 1.20 -7.2 Rgmb RGM domain family, member B
16855 1.00 -6.4 Lgals4 Lectin, galactose binding, soluble 4
Cell communication and signal trasduction
12154 1.09 -4 Bmp10 Bone morphogenetic protein 10
13643 1.02 -7.6 Efnb3 Ephrin B3
14463 1.01 -8 Gata4 GATA binding protein 4
15874 0.96 -40 Iapp Islet amyloid polypeptide
16333 0.85 -23.2 Ins1 Insulin I
14526 0.91 -21.6 Gcg Glucagon
70497 0.86 -8 Arhgap17 Rho GTPase activating protein 17
232201 0.83 -7.6 Arhgap25 Rho GTPase activating protein 25
110052 1.00 -8.4 Dek DEK oncogene (DNA binding) 16
14915 0.98 -13.6 Guca2a Guanylate cyclase activator 2a (guanylin)
212307 0.81 -7.2 Mapre2 Microtubule-associated protein, RP/EB family, member 2Molecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
Page 6 of 16
(page number not for citation purposes)
20844 1.15 -13.6 Stam Signal transducing adaptor molecule
66042 0.85 -14.8 Sostdc1 Sclerostin domain containing 1
68799 1.20 -7.2 Rgmb RGM domain family, member B
80718 0.91 -6.4 Rab27b RAB27b, member RAS oncogene family
18386 0.93 -6 Oprd1 Opioid receptor, delta 1
67709 0.88 -13.6 Reg4 Regenerating islet-derived family, member 4
Cell cycle and cell proliferation
76499 1.02 -8.8 Clasp2 CLIP associating protein 2
16333 0.85 -23.2 Ins1 Insulin I
16334 0.98 -40 Ins2 Insulin II
212307 0.81 -7.2 Mapre2 Microtubule-associated protein, RP/EB family, member 2
22268 0.90 -6 Upk1b Uroplakin 1B
14526 0.91 -21.6 Gcg Glucagon
212307 0.81 -7.2 Mapre2 Microtubule-associated protein, RP/EB family, member 2
57263 1.11 -28 Retnlb Resistin like beta
12154 1.09 -4 Bmp10 Bone morphogenetic protein 10
17831 1.02 -40 Muc2 Mucin 2 19
17063 0.91 -60 Muc13 Mucin 13, epithelial transmembrane
Transporter and binding activity
11773 1.09 -14.8 Ap2m1 Adaptor protein complex AP-2, mu1
80718 0.91 -6.4 Rab27b RAB27b, member RAS oncogene family
56185 1.00 -19.2 Hao3 Hydroxyacid oxidase (glycolate oxidase) 3
110052 1.00 -8.4 Dek DEK oncogene (DNA binding) 16
12829 0.98 -10.8 Col4a4 Procollagen, type IV, alpha 4
16467 1.13 -11.6 Atcay Ataxia, cerebellar, Cayman type homolog (human)
13487 0.95 -20 Slc26a3 Solute carrier family 26, member 3
216156 0.92 -4 Wdr18 WD repeat domain 18
69008 1.23 -6.4 Cab39l Calcium binding protein 39-like
12351 0.84 -4 Car4 Carbonic anhydrase 4
72832 0.93 -14.8 Crtac1 Cartilage acidic protein 1
75600 1.20 -8 Calml4 Calmodulin-like 4
Apoptosis
15874 0.96 -40 Iapp Islet amyloid polypeptide
17831 1.02 -40 Muc2 Mucin 2 19
71361 1.15 -8 Amid Apoptosis-inducing factor, mitochondrion-associated 2
16334 0.98 -40 Ins2 Insulin II
17063 0.91 -60 Muc13 Mucin 13, epithelial transmembrane
Transcription activity
109275 0.94 -4 Actr5 ARP5 actin-related protein 5 homolog (yeast)
71458 0.89 -6 Bcor Bcl6 interacting corepressor
14463 1.01 Gata4 GATA binding protein 4
Epigenetic and chromatin modification
213742 1.00 -8.8 Xist Inactive X specific transcripts
75796 0.86 -4 Cdyl2 Chromodomain protein, Y chromosome-like 2
Inflammatory and immune response
21786 0.90 -10.8 Tff3 Trefoil factor 3, intestinal
15101 0.90 -7.6 H60 Histocompatibility 60
94071 1.00 -4 Clec2h C-type lectin domain family 2, member h
Cell differentiation
12154 1.09 -4 Bmp10 Bone morphogenetic protein 10
14463 1.01 -8 Gata4 GATA binding protein 4
72324 0.86 -4 Plxdc1 Plexin domain containing 1
20755 1.31 -16 Sprr2a Small proline-rich protein 2A
22268 0.90 -6 Upk1b Uroplakin 1B
75770 0.85 -8.4 Brsk2 BR serine/threonine kinase 2
Maintenance of cell polarity and shape
76499 1.02 -8.8 Clasp2 CLIP associating protein 2
20755 1.31 -16 Sprr2a Small proline-rich protein 2A
Ref.* = References identifying genes previously shown to have deregulated expression in pancreatic cancer
Table 2: Downregulated genes in primary pancreatic tumors. Relative fold change in primary pancreatic tumors compared to normal 
pancreas (PT/NP) and in liver metastatic lesions compared to primary pancreatic tumors (LM/PT) (Continued)Molecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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Selected genes showing up- or down regulation of mRNA expression by semi quantitative RT-PCR Figure 2
Selected genes showing up- or down regulation of mRNA expression by semi quantitative RT-PCR. A) All 
selected genes showed expression pattern similar to microarray data upon confirmation by sqRT-PCR. A representative data 
from four Ela-c-myc pancreatic tumors, liver metastatic lesions and normal pancreas is presented. B) RT-PCR showing repre-
sentative differentially expressed genes in liver metastatic lesions compared to primary pancreatic tumors and normal pan-
creas. C) Two genes, Igfbp1 and Serpina1a, were verified in human pancreatic cancer cell lines with high (High-met) and low 
metastatic (Low-met) potentials. Expression patterns of both genes were consistent with the murine microarray and RT-PCR 
data. D) RT-PCR was performed on RNA from primary pancreatic tumors (PT), liver metastatic lesions (LM) and normal pan-
creas (NP) with three overlapping primer sets spanning the region from exon 1 to 10. Primary pancreatic tumors showed pres-
ence of both wild type Wt1 and Wt1 variant without exon 5, while metastatic lesions either lacked expression or had low 
levels of Wt1 gene expression (showed a smaller size non-specific PCR product only).
A B
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β β β β-actin
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Table 3: Upregulated genes in liver metastatic lesions. Relative fold change in liver metastatic lesions compared to primary pancreatic 
tumors (LM/PT) and in primary pancreatic tumors compared to normal pancreas (PT/NP)
Entrez Gene # Fold change 
LM/PT
Fold change 
PT/NP
Gene Symbol Gene description Ref.*
Transporter activity
27413 5.1 0.6 Abcb11 ATP-binding cassette, sub-family B (MDR/TAP), member 11
12870 11.8 0.9 Cp Ceruloplasmin
107141 4.2 1.1 Cyp2c37 Cytochrome P450, family 2. subfamily c, polypeptide 37
76279 9.1 0.6 Cyp2d26 Cytochrome P450, family 2. subfamily d, polypeptide 26
13107 7.8 0.3 Cyp2f2 Cytochrome P450, family 2, subfamily f, polypeptide 2
14263 11.3 0.4 Fmo5 Flavin containing monooxygenase 5
268756 9.0 0.5 Gulo Gulonolactone (L-) oxidase
20493 8.3 0.3 Slc10a1 Solute carrier family 10 member 1
69354 8.3 1.0 Slc38a4 Solute carrier family 38, member 4
28253 4.9 0.9 Slco1b2 Solute carrier organic anion transporter family, member 1b2
Cellular metabolism
67758 10.6 0.3 Aadac Arylacetamide deacetylase (esterase)
208665 11.4 0.3 Akr1d1 Aldo-keto reductase family 1, member D1
11806 43.3 0.8 Apoa1 Apolipoprotein A-I
238055 12.2 0.6 Apob Apolipoprotein B
12116 33.0 0.6 Bhmt Betaine-homocysteine methyltransferase
14121 9.3 0.7 Fbp1 Fructose bisphosphatase 1
227231 33.6 0.3 Cps1 Carbamoyl-phosphate synthetase 1
231396 14.8 1.0 Ugt2b36 UDP glucuronosyltransferase 2 family, polypeptide B36
15233 6.9 0.4 Hgd Homogentisate 1, 2-dioxygenase
15483 4.2 0.2 Hsd11b1 Hydroxysteroid 11-beta dehydrogenase 1
13850 7.8 0.4 Ephx2 Epoxide hydrolase 2, cytoplasmic
13077 7.0 0.8 Cyp1a2 Cytochrome P450, family 1, subfamily a, polypeptide 2
54150 18.2 0.5 Rdh7 Retinol dehydrogenase 7
72094 7.4 1.0 Ugt2a3 UDP glucuronosyltransferase 2 family, polypeptide A3
103149 6.3 0.6 Upb1 Ureidopropionase, beta
16922 5.4 0.4 Phyh Phytanoyl-CoA hydroxylase
Calcium binding activity
19733 11.6 0.5 Rgn Regucalcin
14067 6.9 0.5 F5 Coagulation factor V
16426 48.0 1.0 Itih3 Inter-alpha trypsin inhibitor, heavy chain 3
Cell organization and biogenesis
11625 40.5 0.9 Ahsg Alpha-2-HS-glycoprotein
19699 5.5 0.5 Reln Reelin
16008 6.0 1.0 Igfbp2 Insulin-like growth factor binding protein 2
14080 74.7 1.0 Fabp1 Fatty acid binding protein 1, liver
Protease Inhibitor activity
20700 24.9 4.1 Serpina1a Serine (or cysteine) peptidase inhibitor, clade A, member 1a 25, 51
20702 100.1 0.4 Serpina1c Serine (or cysteine) peptidase inhibitor, clade A, member 1c
59083 22.8 0.3 Fetub Fetuin beta
Inflammatory and Immune response
12628 4.4 1.1 Cfh Complement component factor h
17175 4.5 1.0 Masp2 Mannan-binding lectin serine peptidase 2
11625 40.5 0.9 Ahsg Alpha-2-HS-glycoprotein
15439 14.4 7.6 Hp Haptoglobin
18405 15.8 1.4 Orm1 Orosomucoid 1
12583 8.4 0.8 Cdo1 Cysteine dioxygenase 1, cytosolic
13850 7.8 0.4 Ephx2 Epoxide hydrolase 2, cytoplasmic
11699 90.2 0.2 Ambp Alpha 1 microglobulin/bikunin 28
Cell Adhesion
12558 4.7 1.0 Cdh2 Cadherin 2
14067 6.9 0.5 F5 Coagulation factor V
16008 6.0 1.0 Igfbp2 Insulin-like growth factor binding protein 2
19699 5.5 0.5 Reln Reelin
17175 4.5 1.0 Masp2 Mannan-binding lectin serine peptidase 2
14080 74.7 1.0 Fabp1 Fatty acid binding protein 1, liver
Cell growth and cell cycleMolecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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14080 74.7 1.0 Fabp1 Fatty acid binding protein 1, liver
16008 6.0 1.0 Igfbp2 Insulin-like growth factor binding protein 2
11625 40.5 0.9 Ahsg Alpha-2-HS-glycoprotein
Cell motility and migration
12558 4.7 1.0 Cdh2 Cadherin 2
19699 5.5 0.5 Reln Reelin
16841 4.8 0.6 Lect2 Leukocyte cell-derived chemotaxin 2
20315 4.5 0.1 Cxcl12 Chemokine (C-X-C motif) ligand 12
12738 2.8 0.3 Cldn2 Claudin 2
Cell communication and Signal Transduction
208665 11.4 0.3 Akr1d1 Aldo-keto reductase family 1, member D1
22139 38.8 0.1 Ttr Transthyretin
16008 6.0 1.0 Igfbp2 Insulin-like growth factor binding protein 2
20526 13.1 0.3 Slc2a2 Solute carrier family 2, member 2
238055 12.2 0.6 Apob Apolipoprotein B
50765 4.4 0.7 Trfr2 Transferrin receptor 2
107146 4.7 0.7 Glyat Glycine-N-acyltransferase
51811 5.7 0.7 Clec4f C-type lectin domain family 4, member f
14080 74.7 1.0 Fabp1 Fatty acid binding protein 1, liver
56720 4.0 0.8 Tdo2 Tryptophan 2,3-dioxygenase
11625 40.5 0.9 Ahsg Alpha-2-HS-glycoprotein
353283 4.1 42.0 Eras ES cell-expressed Ras
19699 5.5 0.5 Reln Reelin
16006 28.1 0.7 Igfbp1 Insulin-like growth factor binding protein 1 28,30,31
Ref.* = References identifying genes previously shown to have deregulated expression in pancreatic cancer
Table 3: Upregulated genes in liver metastatic lesions. Relative fold change in liver metastatic lesions compared to primary pancreatic 
tumors (LM/PT) and in primary pancreatic tumors compared to normal pancreas (PT/NP) (Continued)
creas in the wild type littermates, Igf2 expression was dra-
matically increased (Fig 3A). All three receptors for Igf1
and Igf2 showed only slight increase in their expression,
on the other hand all Igf binding proteins (Igfbp1, Igfbp2,
Igfbp3, Igf2bp1 etc.) were downregulated compared to
normal pancreas. Western blot analysis confirmed
increased expression of cleaved, active form of Igf2 (Fig
3B).
Identification of potential metastasis promoting genes in 
c-myc induced pancreatic tumors
As mentioned above, we identified a small number of
genes that were under various functional categories in
metastatic tissues, which were either significantly upregu-
lated or downregulated compared to PT. Interestingly,
genes that were downregulated in liver metastatic lesions
were comparatively much fewer than upregulated genes.
Table 3 shows 4-fold higher and Table 4, 4-fold lower
expression levels in LM compared to PT. Most of the
highly upregulated genes such as Cp, Apoa1, Ttr in liver
metastatic lesions are known biomarkers for the detection
of ovarian or other types of cancer [22-24]. Other highly
upregulated genes were related to protease inhibition
such as Serpina1a, Serpina1c, Ambp [25-27]and insulin
growth factor binding proteins such as Igfbp1 and Ifgbp2
[28-31], which have been shown to be upregulated in
human pancreatic cancer as well as in the animal models
of either pancreatic cancer or other types of cancer. For the
verification of some of these genes, we selected two upreg-
ulated and two downregulated genes, that showed striking
differences from primary pancreatic tumors. In line with
our mocroarray data, all LM samples verified by RT-PCR
showed highly consistent results (Figure 2B).
Decreased or lost expression of Wt1 mRNA in primary 
pancreatic tumors
Wt1 is a transcription factor and has been found to be
overexpressed in several types of cancers with poor prog-
nosis. Our microarray data showed two-fold higher
expression of the Wt1 gene in PT samples compared to NP
samples. RT-PCR with a pair of primers that amplify exons
1 to 7 could detect Wt1 mRNA in PT but not in NP and LM
(Fig. 2D). Interestingly, liver metastatic lesions expressed
a lower molecular species of mRNA. We purified the
higher band from primary tumors and the lower band
from liver metastatic lesions and sequenced the PCR prod-
ucts. The results showed that the Wt1 mRNA in PT con-
tained both wild type Wt1 and Wt1 variant without exon
5 (-51 nt). The slight difference in length could be visual-
ized on agarose gel when the PCR products were separated
further (Fig. 2D, amplified zone). On the other hand,
sequencing results of the band in liver metastatic lesions
showed that it was a product of Uroc1 (urocanase domain
containing 1) gene, not Wt1. Comparison of the primer
sequences with the mouse Uroc1 cDNA (NM_144940)
showed high homology, and therefore a non-specificMolecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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band (Uroc1) was amplified with this primer pair. Since
human Uroc1 gene is highly expression in hepatoblast-
oma than in fetal liver [32], it is possible that Uroc1 is
preferentially expressed in liver tumors and thus may
serve as a marker. PCR with another pair of primers that
amplified nt1444-1943 region of the mRNA also showed
that LM expressed much lower levels of Wt1. Considering
that a tissue is heterogeneous in cell types, it is reasonable
to assume that the Wt1 mRNA detected in LM was derived
from stromal tissue whereas the cancer cells might have
lost Wt1 expression.
Real-time Quantitative Reverse Transcription-PCR 
Validation
To confirm the array gene expression data, we performed
quantitative reverse transcription-PCR (qRT-PCR) for a
selected set (n = 10) of genes and the representative data
for three genes are shown in Table 4. Although the extent
of measured values detected by the two methods varied,
an overall pattern concordance between qRT-PCR and
Affymetrix cDNA array experiments was observed (i.e.,
same trend of induction or suppression was detected by
both methods for each target genes). This difference may
be due to probe design or the GeneChip system hybridi-
zation conditions. For all qRT-PCR, primers specific to β-
actin were used as a control to normalize each experiment.
Results are presented in Table 5.
Verification of microarray data in human pancreatic 
cancer cell lines
A panel of human pancreatic cancer cell lines that were
reportedly to have high or low metastatic potential in
immunodeficient mouse models were used to verify the
data from Ela-c-myc model of primary and metastatic pan-
creatic tumors. Cell lines with high metastatic potential
include PANC28, CoLo357fg, L3.6pl and low- or non-
metastatic potential include PANC1 and BxPC3. We veri-
fied two genes in human cell lines, Igfbp1 and Serpina1a,
these genes were highly upregulated in liver metastaic tis-
sues compared to primary pancreatic tumors from trans-
genic mice. Expression patterns of both genes were
consistent with the murine microarray and RT-PCR data
(Fig. 2C).
Discussion
In this study, we report the genome-wide expression pro-
files of primary pancreatic tumors and liver metastatic
lesions from Ela-c-myc transgenic mice, or normal pan-
creas from wild-type mice. cDNA microarray analysis
showed several gene clusters under various functional cat-
egories in primary or metastatic pancreatic tumors of Ela-
c-myc transgenic mice that differ from normal pancreas of
non-transgenic littermates. Notably, increased expression
was observed for a large number of genes related to ribos-
omal biogenesis, maturation and ribosome assembly in
primary or metastatic pancreatic tumors. Previous studies
by others have also shown enhanced expression of genes
related to ribosomal proteins, rRNA maturation and
ribosome assembly, in addition to enhanced expression
of many translation initiation and elongation factors in c-
Myc overexpressing cells [33-35]. Thus, our model recapit-
ulates the experimental observations and key features of c-
Myc overexpressing tumors.
Genes involved in posttranscriptional regulation was a
major functional category of upregulated genes in both PT
and LM compared to NP samples, we observed changes in
expression for splicing factors, RNA binding/pre-mRNA
processing factors and spliceosome related genes, indicat-
ing that events related to RNA processing may play critical
roles in pancreatic tumor development and progression
induced by c-Myc. More than 50% of human genes
undergo alternative splicing, and this type of RNA process
has recently become an emerging topic in molecular and
clinical oncology [36-38]. Our data showed upregulation
Expression of IGF family genes and proteins Figure 3
Expression of IGF family genes and proteins. A) 
Microarray data show that expression of Igf2 is about 10 fold 
higher in pancreatic tumors compared to liver metastatic 
lesions and normal pancreas from Ela-myc transgenic mice. 
While other IGF family proteins only showed modest change. 
B) Western blot analysis of Insulin like growth factors and 
their receptor proteins. Western blot was performed in cell 
lysates prepared from primary pancreatic tumors (PT), liver 
metastatic lesions (LM) from Ela-c-myc transgenic mice and 
normal pancreas (NP) from wild type littermates. Consistent 
with microarray data, PT samples showed noticeably higher 
protein levels compared to NP samples. A representative 
data from four PT and four NP samples are presented.
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of several splicing factors from the SR family such as Sfrs1,
Sfrs2, Sfrs3, Sf3b in both primary and metastatic tumors
compared to normal pancreas. SR proteins represent a
family of essential splicing factors, which are character-
ized by extensively phosphorylated serine-arginine rich
domains [39]. SR proteins recognize splice sites and,
depending on their relative levels, these proteins can
influence alternative RNA processing [40].
Other groups of genes that were upregulated are involved
in DNA replication, cell proliferation and cell cycle regu-
lation; chromosome organization and biogenesis; and
signal transduction. Many genes are related to the mainte-
nance of chromosomal structure and integrity such as
minichromosome maintenance (Mcm)2, Mcm5, Mcm10,
structural maintenance of chromosome (Smc)2l1,
Smc4l1, Smc5l1, Rad51, Brca1 and Centromere compo-
nent (Cenp-I). The entire Mcm protein family (Mcm2-7)
is essential in regulating the replication of DNA. Amplifi-
cation of genes in the Mcm family has been detected in
various cancer cells [41]. Their upregulation may deregu-
late the complete and accurate DNA replication and thus
result in failure to maintain the genetic integrity of
affected cells. Smc family proteins are integral compo-
nents of the machinery that modulates chromosome
structure for mitosis [42]. Similarly, Rad51, brca1 and
Cenp-I play a role in maintenance of genetic integrity
[43,44]. We also noticed increased expression of some X-
linked genes related to signal transduction such as Rsk4,
Dusp9 and S100g, which have not been reported previ-
ously in pancreatic tumors.
Table 4: Downregulated genes in liver metastatic lesions. Relative fold change in liver metastatic lesions compared to primary 
pancreatic tumors (LM/PT) and in primary pancreatic tumors compared to normal pancreas (PT/NP)
Entrez Gene # LM/PT PT/NP Gene Symbol Gene description Ref.*
Cell communication and Signal transduction
22329 0.5 23.5 Vcam1 Vascular cell adhesion molecule 1
58194 0.4 4.0 Sh3kbp1 SH3-domain kinase binding protein 1
15186 0.1 15.0 Hdc Histidine decarboxylase
11438 0.2 4.9 Chrna4 Cholinergic receptor, nicotinic, alpha polypeptide 
4
12524 0.6 4.6 Cd86 CD86 antigen
93761 0.2 4.2 Smarca1 SWI/SNF related, regulator of chromatin, 
subfamily a, member 1
Cell motility and migration
12767 0.7 4.7 Cxcr4 Chemokine (C-X-C motif) receptor 4 25
17381 2.8 7.6 Mmp12 Matrix metallopeptidase 12 16
11438 0.2 4.9 Chrna4 Cholinergic receptor, nicotinic, alpha polypeptide 
4
Cell Adhesion
12505 0.6 5.3 Cd44 CD44 antigen 11
22329 0.5 23.5 Vcam1 Vascular cell adhesion molecule 1
Cell death and apoptosis
18616 0.2 11.2 Peg3 Paternally expressed 3
11801 0.6 31.1 Cd5l CD5 antigen-like
58194 0.4 4.0 Sh3kbp1 SH3-domain kinase binding protein 1
Inflammatory and Immune response
20210 0.1 14.1 Saa3 Serum amyloid A 3
58194 0.4 4.0 Sh3kbp1 SH3-domain kinase binding protein 1
15186 0.1 15.0 Hdc Histidine decarboxylase
Ref.* = References identifying genes previously shown to have deregulated expression in pancreatic cancer
Table 5: Quantitative RT-PCR. Relative quantity of mRNA expression in PT, LM and NP tissues measured by quantitative real time 
PCR
Relative fold change
Genes PT1 LT1 PT2 LT2 PT3 LT3 NP1 NP2
Igfbp1 14.4 70.0 2.0 20.0 10.0 90.0 2.0 2.0
Sepina1a 16.9 4.9 28.9 78.4 14.4 40.0 2.0 2.0
Peg3 0.4 0.2 4.9 10.0 16.0 8.1 2.0 2.0
β-actin 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0Molecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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Intriguingly, we observed highly upregulated expression
of Igfbp1 and Serpina1 in liver metastatic tissues com-
pared to primary pancreatic tumors and normal pancreas.
Verification of Igfbp1 and Serpina1 by RT-PCR and quan-
titative PCR showed strong expression in liver metastatic
lesions but there was a lack of expression of these genes in
primary pancreatic tumors or normal pancreas. Similarly,
both these genes also showed higher expression in highly
metastatic human pancreatic cell lines (PANC28,
CoLo357fg, L3.6pl) and lower expression levels in less-
metastatic cell lines (PANC1 and BxPC3). Several studies
have described the inhibitory and potentiating activities
of both Serpina1 and Igfbp1 in a variety of cells [45-47].
Igfbp1 interacts with α5β1 integrin, influencing cell adhe-
sion and migration. Jones et al. [48] first reported the
increased migration of Chinese hamster ovary cells trans-
fected to express human Igfbp1. Increased expression of
several Igfbps has also been reported in human pancreatic
cancer [28-31]. Serpins are endogenous inhibitors of ser-
ine protease activity in vivo [49,50] and a large number of
studies support the notion that proteases play an impor-
tant role in the progression of malignant tumors. There-
fore, the expression of proteinase inhibitors is considered
to be an anti-malignant event. Serpina1, a major inhibitor
of human serine proteases in serum, is produced mainly
by the liver, but also by extra-hepatic cells, including neu-
trophils and certain cancer cells [51,52]. However, clinical
studies have shown that high circulating levels of
Serpina1 directly correlate with tumor progression
[53,54]. Immunohistochemical studies revealed that
patients with Serpina1-positive lung adenocarcinomas
had a worse prognosis than Serpina1-negative ones [55].
More interestingly, both Serpina1 and Igfbp1 have been
demonstrated to play a role in human invasive and meta-
static pancreatic cancer. Together these studies and our
findings suggest that Igfbp1 and Serpina1 may play criti-
cal roles in tumor progression in vivo, and are potential
candidates for therapeutic interventions.
We also compared our gene expression profiles with pub-
lished data on human pancreatic cancer tissues or cell
lines. Gene expression pattern of many genes such as
Serpina1, Igfbp1, Wt1, CD44, MMP12, CXCR4, Muc2,
Dek, Capza1, Bcra1, Birc5, S100g, Claudin-18, RAD51,
Mcm2, Mcm4, Mcm7, Cyclin B2, splicing factor 3b,
Nap1l1 etc. (please see Tables 1, 2, 3 and 4for references)
was similarly reported in other studies and therefore pro-
vide a validation for our model.
Conclusion
We show differential gene expression profiles under sev-
eral functional categories in normal pancreas, primary
pancreatic tumors and liver metastases. We identified two
genes, Igfbp1 and Serpina1, which were overexpressed
only in liver metastatic lesions suggesting that these genes
are likely to be involved in the establishment of metas-
tases in Ela-myc transgenic animal model. In addition,
metastatic lesions appear to have low levels or absence of
Wt1 gene expression while primary tumors express at least
two major variants (+ exon 5 or - exon 5) Wt1 transcripts.
Igfbp1 and Serpina1 may serve as clinically interesting
biomarkers are likely to be useful for prognostic or thera-
peutic purposes in metastatic pancreatic cancer.
Methods
Ela-myc transgenic mice
We used Ela-myc transgenic mice with a FVB background,
this strain was generated by crossbreeding of C57BL/6xSJL
background Ela-myc [5] mice (obtained from Dr. Sand-
gren at the University of Wisconsin) with a FVB strain. The
F1 mice were crossed together to generate F2 transgenic
mice and some of the F2 mice were crossed to yield F3
mice. The F2 and F3 transgenic mice and their wild type
littermates were used in this study.
Human Pancreatic cancer cell lines
A panel of human pancreatic cell lines, PANC1, PANC-28,
CoLo357, L3.6pl and BxPC3, were used to verify the
microarray data. All pancreatic cell lines were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum,
penicillin and streptomycin. Cells were harvested when
they were about 80–90% confluent for RNA isolation.
cDNA microarray
Primary pancreatic cancer tissue, its corresponding liver
metastatic lesion and normal pancreatic tissues were used
to prepare RNA using the RNeasy mini kit (Qiagen) per
manufacturer's instructions. Assurance of quality assess-
ment and microarray analysis were carried out by person-
nel in the Applied Genomics Technology Center (Center
for Molecular Medicine and Genetics, Wayne State Uni-
versity). Briefly, biotin-labeled RNA fragments were pro-
duced from 1 µg of RNA by first synthesizing double-
stranded cDNA followed by in vitro transcription and frag-
mentation reactions. A hybridization cocktail, containing
the fragmented cRNA, probe array controls, bovine serum
albumin, and herring sperm DNA, was prepared and
hybridized at 45°C for 16 h to the High Density Mouse
Genome M430-2 containing 45101 probesets (Affymetrix
Inc., Santa Clara, CA). The hybridized probe array was
washed, and bound biotin-labeled cRNA was detected
with streptavidin-phycoerythrin conjugate. Each probe
array was scanned twice (Hewlett-Packard GeneArray
Scanner), the images were overlaid, and the average inten-
sities of each probe cell were compiled. Microarray was
repeated three times for each condition (LM, PT, NP).
cDNA microarray data analysis
High density microarray image files were interpreted and
quality assessed to Affymetrix standards in GCOS 1.1 asMolecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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Table 6: List of primer. Primer sets for qRT-PCR and sqRT-PCR
Gene name Accession No. Quantitative or sqRT-PCR primer sequence
CXCR4
Upstream D87747 CATGGAACCGATCAGTGTGA (325)*
Downstream TTTCCCAAAGTACCAGTCAGC
MMP2
Upstream NM_008610 CTGTGTTCTTCGCAGGGAAT (433)
Downstream TGTGCAGCGATGAAGATGAT
Snail2
Upstream NM_011415 TTCCTCTGACACTTCATCCAA (474)
Downstream TTGGAGCAGTTTTTGCACTG
E-tcad
Upstream NM_009864 CCTGCCAATCCTGATGAAAT (329)
Downstream TCAGGGA AGGAGCTGAAAGA
Fgf13
Upstream AF020737 CATTTTCTGCCCAAACCACT (378)
Downstream AATGCTTGGCACTCTTTTGC
Rsk4
Upstream BB402211 GTGGGTGCCAAAGTTTTGAT (351)
Downstream CAAACCACATGGAAATCAGG
MIF
Upstream NM_010798.1 ACTACAGTAAGCTGCTGTGTGG (208)
Downstream ATCGCTACCGGTGGATAAAC
Mcm7
Upstream NM_008568.1 ACCGCGAAGTCAGTACACAA (208)
Downstream GATGGTCTGCTGCTCCATAA
Ttr
Upstream NM_013697.1 TGGAAGACACTTGGCATTTC (194)
Downstream TGCTACTGCTTTGGCAAGAT
H2Aa
Upstream NM_010378.2 CCTTCATCCCTTCTGACGAT (197)
Downstream CAGGCCTTGAATGATGAAGA
Mrpl19
Upstream NM_026490.2 TGCATCCCATGAAGAAGAGA (183)
Downstream GACATTTGCTCGTTACAAAAGC
Dusp9
Upstream NM_029352.3 CCTGTGCTTGAGCTCTGATT (181)
Downstream GCTCTCCAAATTGGCTGAAT
S100g
Upstream NM_009789.2 CAGCAAAATGTGTGCTGAGA (197)
Downstream CTCCATCGCCATTCTTATCC
Serpina1a
Upstream NM_009243 GCCCTGGCAAATTACATTCT (196)
Downstream CATTGCCTGCATAATCCATC
Peg3
Upstream NM_008817.2 ACCATTCAGGCCTCAGTTTC (205)
Downstream TTTTCTCAAATTCGCTGACG
Igfbp1
Upstream NM_008341 CCTGCCAACGAGAACTCTAT (196)
Downstream GGGATTTTCTTTCCACTCCA
Saa3
Upstream NM_011315.3 GCGAGCCTACTCTGACATGA (196)
Downstream ATTGGCAAACTGGTCAGCTC
Cldn18
Upstream NM_019815.2 GCTGTACGAGCCCTGATGAT (193)
Downstream TGTTGGCAAACACAGACACA
Sfrs1
Upstream NM_173374.3 CACTGGTGTCGTGGAGTTTG (190)
Downstream CTTCTGCTACGGCTTCTGCT
Sfrs2
Upstream NM_013663.3 GCTTTGCTTTCGTCGAATTT (188)
Downstream AGGACTCCTCCTGCGGTAATMolecular Cancer 2008, 7:11 http://www.molecular-cancer.com/content/7/1/11
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Eif2
Upstream NM_026030.2 GGAGTTGCTGAACCGAGTGT (180)
Downstream AGGAGATGTTTGGGTTGACG
Muc13
Upstream NM_010739.1 TGCGTGATGCTACAAAGGAC (195)
Downstream TGTCCTGGCATTTACTGCTG
Igfbp1 (human)
Upstream NM_000596.2 AAGGCACAGGAGACATCAGG (195)
Downstream TATCTGGCAGTTGGGGTCTC
Serpina1 (human)
Upstream NM_001002235.1 TGCCTGATGAGGGGAAACTA (186)
Downstream CCCCATTGCTGAAGACCTTA
WT1(362–970)
Upstream NC_000068 TCCAGCAGCCGGAGCAACCT (608)
Downstream AGGGCGTGTGGCCATAGCTG
WT1(947–1470)
Upstream NC_000068 CGCCCAGCTATGGCCACACG (523)
Downstream ATTGCAGCCTGGGTATGCAC
WT1(1444–1943)
Upstream NC_000068 TTCATGTGTGCATACCCAGG (499)
Downstream GTAGATCCACAGTCGTGTCC
*PCR product size
Table 6: List of primer. Primer sets for qRT-PCR and sqRT-PCR (Continued)
described previously [56]. Expression changes were fil-
tered in DChip for fold change (> 4 fold) between the
experiments. Hierarchical clustering was carried out using
Dchip and ontological analysis of gene expression was
conducted in both OntoExpress in conjunction with
curated pathway analysis using the KEGG Biocarta and
GeneGo systems. At least three samples from each condi-
tion were used for Affymetrix microarray analysis to select
candidate genes. Candidate genes were also confirmed
with semi-quantitative, quantitative RT-PCR analysis and/
or western blot at least 3 times.
Semiquantitative RT-PCR
Total RNA, isolated from the primary or metastatic lesions
and normal pancreas of Ela-c-myc transgenic mice, was
subjected to first-strand cDNA synthesis using an oligo
(dT) primer and Moloney murine leukemia virus (MMLV)
reverse transcriptase (Invitrogen). The primer amplified
products were separated on ethidium bromide containing
1.2% agarose gels. Primers for the semiquantitative and
quantitative detection of target mRNAs are presented in
Table 6.
Real-Time RT-PCR
cDNA from the primary or metastatic lesions Ela-c-myc
transgenic and normal pancreas of wild type mice were
subjected to PCR amplification, a maximum of 2 µl of
each cDNA sample was used per 25-µl PCR reactions. The
real-time measurements were analyzed in triplicate using
an automated Real Time Cycler as described previously
[56]. The relative quantity in primary tumor versus nor-
mal tissue or primary tumor versus metastatic lesion was
normalized to β-actin.
Sequencing of Wilm's tumor suppressor gene (Wt1)
RT-PCR analysis using primers amplified nt947-1470
region of mouse Wt1 mRNA, which covers the first 7
exons, showed that liver metastases (but not primary pan-
creatic tumors) contained a lower molecular weight
mRNA species. To verify the identity of the PCR products
of the higher bands in primary tumor and lower band in
liver metastatic lesions, we sequenced these bands using
forward primer-947 after purifying them from agarose
gels using Gel Extraction Kit (QIAEX II) from Qiagen.
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